Effect of beta-adrenergic blockade on blood pressure variation in patients with moderate hypertension

Clement, D; Bogaert, Marcus; Pannier, R

doi:10.1007/bf00566528

Cited by 19 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus the main effect of atenolol was to lower the blood pressure level around which variations occurred. Clement, Bogaert & Pannier (1977) came to a similar conclusion.…”

Section: Discussionsupporting

confidence: 52%

Atenolol v placebo in mild hypertension: renal metabolic and stress antipressor effects.

Waal‐Manning¹,

Bolli²

1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The effects of 8 week treatment periods of atenolol and placebo on effective renal plasma flow (ERPF), glomerular filtration rate (GFR), plasma renin activity (PRA), oral glucose, fasting lipids and Achilles tendon reflex were compared in a double-blind crossover trial in ten subjects with mild hypertension. 2 Atenolol reduced resting blood pressure and pulse rate but did not prevent the rise in blood pressure and pulse rate in response to three kinds of stress. 3 Mean glomerular filtration rate and effective renal plasma flow were below the normal range during placebo (1.31 ml/s and 7.40 ml/s respectively) but were not significantly different on atenolol (1.23 ml/s and 7.18 ml/s). Serum urea was significantly (P < 0.01) higher on atenolol (6.7 mmol/l) than on placebo (5.6 mmol/l) but serum creatinine did not change. PRA was lower on atenolol (0.42 nmol 1-1 h-') than on placebo (1.01 nmol 1-' h'-). 4 The mean values of fasting cholesterol, triglycerides, ankle jerk contraction time, spirometry, weight, serum potassium, sodium and chloride were similar on atenolol and placebo. 5 Fasting blood sugar was a little higher (P < 0.05) on atenolol and the 1 and 2 h post-glucose serum insulin levels were a little lower (P < 0.01). 6 The cardioselectivity of atenolol does not impair its anti-hypertensive effect and may be associated with less effect on renal function. The metabolic effects of atenolol seem to differ from those of metoprolol.

show abstract

“…Thus the main effect of atenolol was to lower the blood pressure level around which variations occurred. Clement, Bogaert & Pannier (1977) came to a similar conclusion.…”

Section: Discussionsupporting

confidence: 52%

Atenolol v placebo in mild hypertension: renal metabolic and stress antipressor effects.

Waal‐Manning¹,

Bolli²

1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Headaches, which are significantly less common in treated persons, are excluded from this analysis. r53,r56,r63;r22,r25,r29,r36,r39,r92,r95,r96,r105,r108,r114,r119,r120;ACE inhibitors,r15,r20,r21,r23,r26,r34,r66,r203,r9,r19,r30,r139,r140,r158,r195,r253,r254;r9,r24,r28,r31,r65,r79,r82,r136,r138,r170,r171,r182,r215,r216, This varied; some symptoms were not recorded in every trial. c Not statistically significant; however, the upper CI is informative.…”

Section: The Prevalence Of Symptoms Caused By the Drugsmentioning

confidence: 99%

Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy

Law

Wald²,

Morris³

2003

Health Technol Assess

211

View full text Add to dashboard Cite

show abstract

The changing concept of cardiovascular reactivity

Rosenman¹,

Ward²

1988

Stress Med.

View full text Add to dashboard Cite

Cardiovascular reactivity has long been measured in laboratory responses to a wide variety of cognitive and physical stressors, with the hypothesis that exaggerated reactivity plays a pathogenetic role in the development of essential hypertension. However there are few data to support the belief that behavioural differences of cognitive perception of stressors account for observed differences of reactivity. Cardiovascular reactivity in the laboratory does not predict hypertension or account for differences of blood pressure variability in the natural environment. Hypertensives do not exhibit increased blood pressure variability. Antihypertensive therapy consistently fails to lower cardiovascular reactivity in either the laboratory or natural milieu, supporting the dual and largely independent regulation of the basal and reactive blood pressures. It is concluded that there is little support for the use of laboratory stress testing to delineate either the pathogenesis of hypertension, the evaluation of hypertensive subjects, or the efficacy of antihypertensive therapy.

show abstract

Effect of beta-adrenergic blockade on blood pressure variation in patients with moderate hypertension

Cited by 19 publications

References 12 publications

Atenolol v placebo in mild hypertension: renal metabolic and stress antipressor effects.

Atenolol v placebo in mild hypertension: renal metabolic and stress antipressor effects.

Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy

The changing concept of cardiovascular reactivity

Contact Info

Product

Resources

About